Dr. Bruno Strigini
Board of Directors
Board of Directors
With an impressive tenure of over 30 years in the healthcare sector, Dr. Bruno Strigini possesses a rich tapestry of international executive leadership experiences. He has made significant contributions as the President and CEO of Novartis Oncology from 2014 to 2018, showcasing his in-depth expertise and astute leadership in the industry. He also formerly served as the President of Europe/Canada at Merck & Co. His career path has spanned positions at notable organizations like Schering-Plough, UCB, and SmithKline Beecham, where he held significant roles such as President of International operations, President of Japan and Asia-Pacific, Head of Global Marketing and Business Development, and various Managing Director positions.
Dr. Strigini’s current leadership roles include serving as the Chairman of the board of Owkin, a cutting-edge AI and machine learning company specialized in healthcare. Since 2021, he has held a directorial position at Neuraxpharm, a premier European specialty pharmaceutical company focused on treating the central nervous system (CNS). Additionally, he is a partner at OneHealth Partners, a healthcare advisory firm centered on capital raising and strategic transactions in the healthcare sector.
Mr. Strigini holds a Master of Business Administration from IMD business school in Switzerland, a doctorate in pharmacy from the University of Montpellier in France, and a master’s degree in microbiology from Heriot-Watt University in the United Kingdom. He is an elected member of the French National Academy of Pharmacy, and in 2014, he was awarded a doctor honoris causa from Universidad Internacional Menéndez Pelayo in Spain.